Future ATRAG indications

Based on the extensive existing preclinical documentation, the localization of the AT2 receptor in man as well as accumulating clinical data, stimulating the AT2 receptor may be beneficial in a wide range of diseases.

AT2 receptor in disease - preclinical and clinical evidence

Strong scientific foundation for AT2 receptor in diseases of aging as well as acute conditions. AT2 receptor target is upregulated when needed. Vicore has conducted a strategic review of these opportunities and we hope to explore the full potential of ATRAGs also in kidney disease, cardiovascular disease, womens health and central nervous system disorders.

Vicore is developing a broad therapeutic portfolio

Vicore has transformed from a rare disease, single asset company to a platform company with several assets with long patent life for a variety of diseases, some of which could be partnered while others can be taken to the market by Vicore. Vicore has deep AT2 receptor expertise and is well positioned to pursue these opportunities